(IDYA) Ideaya Biosciences - Ratings and Ratios
Cancer Drugs, Oncology Therapies
IDYA EPS (Earnings per Share)
IDYA Revenue
Description: IDYA Ideaya Biosciences August 09, 2025
Ideaya Biosciences Inc (NASDAQ:IDYA) is a biotechnology company listed on the NASDAQ stock exchange. As a biotechnology firm, its primary focus is on developing and commercializing innovative therapies, likely in areas such as oncology, given the industrys current trends.
The companys market capitalization stands at approximately $2.22 billion, indicating a significant presence in the biotechnology sector. The forward Price-to-Earnings (P/E) ratio is 4.65, suggesting that investors have certain expectations for future earnings growth, despite the current lack of profitability, as indicated by a P/E ratio of 0.00. The Return on Equity (RoE) is -29.20%, highlighting the companys current unprofitable status.
Key economic drivers for Ideaya Biosciences include the progress of its pipeline assets, particularly those in clinical development. Success in clinical trials, regulatory approvals, and eventual commercialization of its therapies can significantly impact the companys valuation. Additionally, partnerships or collaborations with larger pharmaceutical companies can also be a crucial factor, as they can provide not only financial benefits but also validation of the companys technologies and approaches.
From a trading perspective, the stocks liquidity appears to be substantial, with an average daily trading volume of 869,314 shares. This liquidity can contribute to tighter bid-ask spreads and reduced volatility not related to fundamental changes in the companys prospects. The stocks beta is 0.031, indicating a very low correlation with the overall market movements, which could be of interest to investors seeking to diversify their portfolios.
To evaluate Ideaya Biosciences potential, investors should closely monitor clinical trial results, regulatory updates, and any strategic partnerships. Key Performance Indicators (KPIs) to watch include the progression of its lead compounds through clinical development stages, the expansion of its pipeline through internal research or in-licensing, and the companys cash runway, given its current negative RoE.
IDYA Stock Overview
| Market Cap in USD | 2,427m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-05-23 |
IDYA Stock Ratings
| Growth Rating | 39.9% |
| Fundamental | 24.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -9.59% |
| Analyst Rating | 4.69 of 5 |
IDYA Dividends
Currently no dividends paidIDYA Growth Ratios
| Growth Correlation 3m | 89.7% |
| Growth Correlation 12m | 3.7% |
| Growth Correlation 5y | 50.3% |
| CAGR 5y | 21.30% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.31 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.88 |
| Sharpe Ratio 12m | -0.28 |
| Alpha | -0.91 |
| Beta | 0.141 |
| Volatility | 52.73% |
| Current Volume | 690.2k |
| Average Volume 20d | 1310.7k |
| Stop Loss | 29.8 (-5.7%) |
| Signal | -0.40 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-331.0m TTM) > 0 and > 6% of Revenue (6% = 420.0k TTM) |
| FCFTA -0.29 (>2.0%) and ΔFCFTA -14.75pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9004 % (prev 5622 %; Δ 3382 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.28 (>3.0%) and CFO -293.7m > Net Income -331.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 12.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (88.5m) change vs 12m ago 13.48% (target <= -2.0% for YES) |
| Gross Margin 90.81% (prev 64.98%; Δ 25.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.69% (prev 1.23%; Δ -0.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.11 (EBITDA TTM -382.4m / Interest Expense TTM -54.2m) >= 6 (WARN >= 3) |
Altman Z'' -10.94
| (A) 0.61 = (Total Current Assets 685.6m - Total Current Liabilities 55.3m) / Total Assets 1.04b |
| (B) -0.74 = Retained Earnings (Balance) -772.5m / Total Assets 1.04b |
| (C) -0.38 = EBIT TTM -385.2m / Avg Total Assets 1.01b |
| (D) -9.45 = Book Value of Equity -771.0m / Total Liabilities 81.6m |
| Total Rating: -10.94 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 24.65
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -16.67% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda 0.23 = 2.46 |
| 6. ROIC - WACC (= -35.28)% = -12.50 |
| 7. RoE -31.35% = -2.50 |
| 8. Rev. Trend -73.47% = -5.51 |
| 9. EPS Trend -16.06% = -0.80 |
What is the price of IDYA shares?
Over the past week, the price has changed by +11.19%, over one month by +16.22%, over three months by +24.65% and over the past year by +7.26%.
Is Ideaya Biosciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IDYA is around 31.35 USD . This means that IDYA is currently overvalued and has a potential downside of -0.79%.
Is IDYA a buy, sell or hold?
- Strong Buy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IDYA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47.1 | 48.9% |
| Analysts Target Price | 47.1 | 48.9% |
| ValueRay Target Price | 34.3 | 8.6% |
IDYA Fundamental Data Overview October 18, 2025
P/E Forward = 4.649
P/S = 346.6934
P/B = 2.4841
Beta = 0.141
Revenue TTM = 7.00m USD
EBIT TTM = -385.2m USD
EBITDA TTM = -382.4m USD
Long Term Debt = 26.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 318.0k USD (from shortTermDebt, last quarter)
Debt = 26.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -88.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.78b USD (2.43b + Debt 26.6m - CCE 669.7m)
Interest Coverage Ratio = -7.11 (Ebit TTM -385.2m / Interest Expense TTM -54.2m)
FCF Yield = -16.67% (FCF TTM -297.3m / Enterprise Value 1.78b)
FCF Margin = -4247 % (FCF TTM -297.3m / Revenue TTM 7.00m)
Net Margin = -4729 % (Net Income TTM -331.0m / Revenue TTM 7.00m)
Gross Margin = 90.81% ((Revenue TTM 7.00m - Cost of Revenue TTM 643.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.71 (Enterprise Value 1.78b / Total Assets 1.04b)
Interest Expense / Debt = 94.25% (Interest Expense 25.1m / Debt 26.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -304.3m (EBIT -385.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.39 (Total Current Assets 685.6m / Total Current Liabilities 55.3m)
Debt / Equity = 0.03 (Debt 26.6m / totalStockholderEquity, last quarter 959.7m)
Debt / EBITDA = 0.23 (negative EBITDA) (Net Debt -88.0m / EBITDA -382.4m)
Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -88.0m / FCF TTM -297.3m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = -31.79% (Net Income -331.0m / Total Assets 1.04b)
RoE = -31.35% (Net Income TTM -331.0m / Total Stockholder Equity 1.06b)
RoCE = -35.59% (EBIT -385.2m / Capital Employed (Equity 1.06b + L.T.Debt 26.6m))
RoIC = -28.82% (negative operating profit) (NOPAT -304.3m / Invested Capital 1.06b)
WACC = 6.46% (E(2.43b)/V(2.45b) * Re(6.53%) + (debt cost/tax rate unavailable))
Discount Rate = 6.53% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 16.45%
Fair Price DCF = unknown (Cash Flow -297.3m)
EPS Correlation: -16.06 | EPS CAGR: 15.31% | SUE: 1.86 | # QB: 1
Revenue Correlation: -73.47 | Revenue CAGR: -79.73% | SUE: -1.35 | # QB: 0
Additional Sources for IDYA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle